Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
Supernus Pharmaceuticals (Nasdaq: SUPN) expects to report third quarter 2025 financial and business results after market close on Tuesday, November 4, 2025. Management will host a conference call and webcast the same day at 4:30 p.m. ET with Jack Khattar, President and CEO, and Tim Dec, SVP and CFO, presenting prepared remarks followed by a Q&A session.
A live webcast will be available in the Events & Presentations section of the investor relations site at www.supernus.com/investors. Participants may pre-register to receive a dial-in number and personalized conference code; dial-in is recommended 15 minutes before the start. A replay will be posted on the investor site and remain available for 60 days after the live call.
Supernus Pharmaceuticals (Nasdaq: SUPN) prevede di riportare i risultati finanziari e aziendali del terzo trimestre 2025 dopo la chiusura del mercato martedì 4 novembre 2025. La direzione terrà una conference call e trasmetterà in webcast lo stesso giorno alle 16:30 ET con Jack Khattar, Presidente e CEO, e Tim Dec, SVP e CFO, che presenteranno osservazioni preparate seguite da una sessione di Q&A.
Un webcast in diretta sarà disponibile nella sezione Eventi e Presentazioni del sito degli investitori all'indirizzo www.supernus.com/investors. I partecipanti possono preregistrarsi per ricevere un numero di accesso e un codice di conferenza personalizzato; si consiglia di chiamare 15 minuti prima dell'inizio. Una registrazione della conferenza sarà pubblicata sul sito degli investitori e rimarrà disponibile per 60 giorni dopo la trasmissione dal vivo.
Supernus Pharmaceuticals (Nasdaq: SUPN) espera reportar los resultados financieros y comerciales del tercer trimestre de 2025 después del cierre del mercado el martes 4 de noviembre de 2025. La gerencia conducirá una conferencia telefónica y transmitirá por webcast el mismo día a las 4:30 p.m. ET, con Jack Khattar, presidente y CEO, y Tim Dec, SVP y CFO, presentando comentarios preparados seguidos de una sesión de preguntas y respuestas.
Un webcast en vivo estará disponible en la sección de Eventos y Presentaciones del sitio de relaciones con inversionistas en www.supernus.com/investors. Los participantes pueden pre-registrarse para recibir un número de marcación y un código de conferencia personalizado; se recomienda marcar 15 minutos antes del inicio. Se publicará una repetición en el sitio de inversores y estará disponible durante 60 días después de la llamada en vivo.
슈퍼너스 파마슈티컬스(Supernus Pharmaceuticals, Nasdaq: SUPN)은 2025년 3분기 재무 및 사업 실적을 2025년 11월 4일 화요일 장 마감 후에 발표할 예정입니다. 경영진은 같은 날 동부표준시 4:30 PM에 개최되는 컨퍼런스 콜 및 웹캐스트를 주최하며, 회장 겸 CEO인 Jack Khattar 와 SVP 및 CFO인 Tim Dec가 준비된 발언을 한 뒤 질의응답 시간을 진행합니다.
라이브 웹캐스트는 투자자 관계 사이트의 이벤트 및 발표 섹션에서 www.supernus.com/investors를 통해 이용할 수 있습니다. 참가자는 다이얼인 번호와 개인화된 컨퍼런스 코드를 받기 위해 사전 등록할 수 있으며, 시작 15분 전까지 전화에 연결하는 것이 권장됩니다. 라이브 콜 이후 60일 동안 투자자 사이트에 재방이 게시됩니다.
Supernus Pharmaceuticals (NYSE: SUPN) prévoit de publier les résultats financiers et commerciaux du troisième trimestre 2025 après la clôture du marché le mardi 4 novembre 2025. La direction animera une conférence téléphonique et diffusera une webcast le même jour à 16 h 30 HE, avec Jack Khattar, Président et PDG, et Tim Dec, SVP et CFO, présentant des remarques préparées suivies d'une séance de questions-réponses.
Un webcast en direct sera disponible dans la section Événements et Présentations du site des relations investisseurs à l'adresse www.supernus.com/investors. Les participants peuvent préenregistrer pour recevoir un numéro d'accès et un code de conférence personnalisé ; il est recommandé d'appeler 15 minutes avant le début. Une rediffusion sera publiée sur le site des investisseurs et restera disponible pendant 60 jours après l'appel en direct.
Supernus Pharmaceuticals (Nasdaq: SUPN) erwartet, die finanziellen und geschäftlichen Ergebnisse des dritten Quartals 2025 nach Börsenschluss am Dienstag, dem 4. November 2025 zu melden. Das Management wird am selben Tag eine Konferenzschaltung durchführen und den Webcast um 16:30 Uhr ET beginnen, wobei Jack Khattar, Präsident und CEO, und Tim Dec, SVP und CFO, vorbereitete Bemerkungen vortragen und eine Q&A-Session folgen wird.
Ein Live-Webcast wird im Bereich Events & Präsentationen der Investor-Relations-Website unter www.supernus.com/investors verfügbar sein. Die Teilnehmer können sich vorab registrieren, um eine Dial-in-Nummer und einen personalisierten Konferenzcode zu erhalten; der Anruf wird 15 Minuten vor Beginn empfohlen. Eine Aufzeichnung wird auf der Investorenseite veröffentlicht und für 60 Tage nach dem Live-Anruf verfügbar sein.
شركة Supernus للأدوية (ناسداك: SUPN) تتوقع أن تبلغ عن نتائجها المالية وأعمالها للـ الربع الثالث 2025 بعد إغلاق السوق يوم الثلاثاء 4 نوفمبر 2025. ستعقد الإدارة مكالمة مؤتمر وبث حي في نفس اليوم في الساعة 4:30 مساءً بتوقيت شرق الولايات المتحدة، وسيقدم جاك ختار رئيس مجلس الإدارة والمدير التنفيذي، وتيم ديك نائب الرئيس الأول والمدير المالي، ملاحظات معدة تليها جلسة أسئلة وأجوبة.
سيكون هناك بث مباشر عبر الويب متاحاً في قسم الأحداث والعروض على موقع علاقات المستثمرين عند www.supernus.com/investors. يمكن للمشاركين التسجيل المسبق لاستلام رقم اتصال ورمز مؤتمر شخصي؛ يُنصح بالاتصال 15 دقيقة قبل البدء. سيُعاد نشر تسجيل للمكالمة على موقع المستثمرين وسيكون متاحاً لمدة 60 يوماً بعد المكالمة الحية.
Supernus Pharmaceuticals (纳斯达克：SUPN) 预计在2025年第三季度的财务和业务业绩将于2025年11月4日（星期二）市场收盘后公布。管理层将在同一天举行电话会议并通过网络广播进行网络直播，时间为美国东部时间下午4:30，由董事长兼首席执行官 Jack Khattar 和高级副总裁兼首席财务官 Tim Dec 发表准备好的发言，随后进行问答环节。
网络直播将在投资者关系网站的“活动与演示”板块提供，网址为www.supernus.com/investors。参与者可以提前注册以获取拨入号码和个性化会议代码；建议在开场前15分钟拨入。回放将发布在投资者网站上，现场结束后60天内可用。
- None.
- None.
ROCKVILLE, Md., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report third quarter 2025 financial and business results after the market closes on Tuesday, November 4, 2025.
Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the third quarter 2025 financial and business results on Tuesday, November 4, 2025, at 4:30 p.m. ET. Following management’s prepared remarks and discussion of business results, the call will be open for questions.
A live webcast will be accessible in the Events & Presentations section of the Company’s Investor Relations website at www.supernus.com/investors.
Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company's Investor Relations website at www.supernus.com/investors. The webcast will be available on the Company’s website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.
For more information, please visit www.supernus.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to sustain and increase its profitability; the Company's ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to increase the number of prescriptions written for each of its products, the products of its subsidiaries, and products acquired through the acquisition of Sage; the Company's ability to increase its net revenue from its products, the products of its subsidiaries, and products acquired through the acquisition of Sage; the Company's ability to commercialize its products, the products of its subsidiaries, and products acquired through the acquisition of Sage; the Company's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; changes to laws and regulations applicable to our industry, the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs; and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
Or
INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com
FAQ
When will Supernus (SUPN) report third quarter 2025 results?
What time is the Supernus (SUPN) Q3 2025 conference call and who will present?
How can investors access the Supernus (SUPN) webcast for the Q3 2025 call?
Do I need to register to join the Supernus (SUPN) conference call on November 4, 2025?
Will there be a replay of the Supernus (SUPN) Q3 2025 conference call and for how long?
